Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board
Verona Pharma plc - American Depositary Shares (VRNA)
US:NASDAQ Investor Relations:
nasdaq.com/symbol/vrna/real-time
Company Research
Source: Business Wire
SCHLIEREN, Switzerland--(BUSINESS WIRE)--Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nearly a decade of experience in private equity, hedge fund investing, and capital markets.Christina Ackermann and Tim Ramdeen have led clinical and commercial companies through product development, growth, and commercialization while raising significant capital. Christina Ackermann succeeds Harry Welten, who resigns after six years on the Board of Directors."Christina and Tim are exceptional leaders. Their broad expertise across commercial and legal affairs as well as their network among inves
Show less
Read more
Impact Snapshot
Event Time:
VRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRNA alerts
High impacting Verona Pharma plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
VRNA
News
- Verona Pharma plc (NASDAQ: VRNA) was given a new $83.00 price target on by analysts at Roth Capital.MarketBeat
- Verona Pharma plc (NASDAQ: VRNA) had its price target raised by analysts at Wells Fargo & Company from $74.00 to $93.00. They now have an "overweight" rating on the stock.MarketBeat
- Verona Pharma plc (NASDAQ: VRNA) had its price target raised by analysts at HC Wainwright from $60.00 to $75.00. They now have a "buy" rating on the stock.MarketBeat
- Verona Pharma PLC (VRNA) Q4 2024 Earnings Call Highlights: Strong Launch of Ohtuvayre Amid ... [Yahoo! Finance]Yahoo! Finance
- Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
VRNA
Sec Filings
- 3/12/25 - Form 144
- 2/28/25 - Form 4
- 2/27/25 - Form S-8
- VRNA's page on the SEC website